An ionizable cationic lipid
Related Products
API Version(s)
45572GMP SM-102
Isomer(s)
34372Lipid 5 38775Lipid M
Labeled Version(s)
9004898SM-102-d4
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SM-102

Item No. 33474

Product Insert (PDF)Technical Brief (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]-octanoic acid, 1-octylnonyl ester
CAS Number
2089251-47-6
Synonyms
  • CAY10779
  • Lipid H
  • LNP-102
Molecular Formula
C44H87NO5
Formula Weight
710.2
Purity
≥98%
Formulation (Request formulation change)
A 100 mg/ml solution in ethanol
Solubility(Learn about Variance in Solubility)
Chloroform: 100 mg/mlEthanol: 100 mg/ml
SMILES
OCCN(CCCCCCCC(OC(CCCCCCCC)CCCCCCCC)=O)CCCCCC(OCCCCCCCCCCC)=O
InChi Code
InChI=1S/C44H87NO5/c1-4-7-10-13-16-17-18-24-32-41-49-43(47)35-29-25-31-38-45(39-40-46)37-30-23-19-22-28-36-44(48)50-42(33-26-20-14-11-8-5-2)34-27-21-15-12-9-6-3/h42,46H,4-41H2,1-3H3
InChi Key
BGNVBNJYBVCBJH-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    25 mg

    $109

    Add

    50 mg

    $164

    Add

    100 mg

    $262

    Add

    250 mg

    $436

    Add
    Cayman Chemical
    Ionizable Lipids – Your Path from R&D to GMP

    Seamlessly bridge your LNP discovery journey from RUO to bulk GLP-tox and GMP excipient-grade material.

    Explore CGMP Lipid Services
    Product Description

    SM-102 is an ionizable cationic lipid (pKa = 6.68) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and plasmid DNA in vitro and in vivo.1,2 It inhibits inward-rectifying potassium currents mediated by human-ether-a-go-go (hERG), also known as Kv11.1, in GH3 rat pituitary cells and MA-10 mouse Leydig cells (IC50s = 108 and 98 µM, respectively).3 Administration of luciferase mRNA in SM-102-containing LNPs induces hepatic luciferase expression in mice.1 LNPs containing SM-102 and Q1-SM-102 (Item No. 41239) as a cationic lipid pair (CLP) and encapsulating a luciferase reporter induce luciferase expression in the lungs and spleen in mice.4 Intramuscular immunization of LNPs containing SM-102 and encapsulating mRNA encoding the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum SARS-CoV-2 spike glycoprotein-specific IgG titers in mice.5 LNPs containing SM-102 and encapsulating mRNA encoding β-catenin increase bone volume in a mouse model of tibia fracture repair when administered via injection to the fracture callus.6 Formulations containing SM-102 have been used in the development of LNPs for delivery of mRNA-based vaccines.

    Read our statement on SM-102 for research use only

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Sabnis, S., Kumarasinghe , E.S., Salerno, T., et al. A novel amino lipid series for mRNA delivery: Improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26(6), 1509-1519 (2018).

    2. Zhang, W., Pfeifle, A., Lansdell, C., et al. The expression kinetics and immunogenicity of lipid nanoparticles delivering plasmid DNA and mRNA in mice. Vaccines (Basel) 11(10), 1580 (2023).

    3. Cho, H.-Y., Chuang, T.-H., and Wu, S.-N. Effective perturbations on the amplitude and hysteresis of Erg-mediated potassium current caused by 1-octylnonyl 8-[(2-hydroxyethyl)[6-oxo-6(undecyloxy)hexyl]amino]-octanoate (SM-102), a cationic Lipid. Biomedicines 9(10), 1367 (2021).

    4. Zeng, G., He, Z., Yang, H., et al. Cationic lipid pairs enhance liver-to-lung tropism of lipid nanoparticles for in vivo mRNA delivery. ACS Appl. Mater. Interfaces 16(20), 25698-25709 (2024).

    5. Chen, K., Fan, N., Huang, H., et al. mRNA vaccines against SARS-CoV-2 variants delivered by lipid nanoparticles based on novel ionizable lipids. Adv. Funct. Mater. 32(39), (2022).

    6. Nelson, A.L., Mancino, C., Gao, X., et al. β-catenin mRNA encapsulated in SM-102 lipid nanoparticles enhances bone formation in a murine tibia fracture repair model. Bioact. Mater. 39, 273-286 (2024).

    Product Citations

    Jiang, A.Y., Cristian, A., Brooks, D.L., et al. Efficient prime editing in vivo and in vitro using lipid nanoparticles. Nat. Nanotechnol. (2026).

    Han, E.L., Kim, D., Murray, A.M., et al. High-throughput in vivo screening identifies structural factors driving mRNA lipid nanoparticle delivery to the brain. ACS Nano 20(4), 3807-3820 (2026).

    Tomczyk, M., Kraszewska, I., Li, G., et al. Chordin-like 1 mRNA therapy for acute myocardial infarction. Circulation 152(22), 1586-1589 (2025).

    Frey, A., Clulo, K., Fei, Y., et al. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Rep. 44(10), 116359 (2025).